Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Jul 31, 2026, 10:07 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 12:03 PMBenzinga Newsdesk
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;
New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on
PHAT
BenzingaOct 8, 2026, 12:05 PMBenzinga Newsdesk
Phathom Pharmaceuticals To Present Three Voquezna GERD Analyses At ACG 2026 Annual Meeting, October 9-14
PHAT
SEC EDGARSep 29, 2026, 8:45 PMSEC EDGAR
8-K filing — Phathom Pharmaceuticals, Inc. (PHAT)
Filed: 2026-09-29 AccNo: 0001193125-26-407696 Size: 144 KB Item 8.01: Other Events
PHAT
BenzingaSep 29, 2026, 12:05 PMBenzinga Newsdesk
Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first
PHAT